Tags : Quethera

Astellas Announces Acquisition of Quethera’s Ophthalmic Gene Therapy Program

Shots: The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s  Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells to treat glaucoma In pre-clinical models, this gene therapy improved survival rates of retinal ganglion cells (RGCs) in pre-clinical models Click here to read […]Read More